{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T01:06:28Z","timestamp":1769562388655,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.taap.2023.116604","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T10:39:08Z","timestamp":1686825548000},"page":"116604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome"],"prefix":"10.1016","volume":"473","author":[{"given":"Kehinde S.","family":"Olaniyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie E.","family":"Areloegbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel D.","family":"Areola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaiah W.","family":"Sabinari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adedamola A.","family":"Fafure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard D.","family":"Agbana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chukwubueze L.","family":"Atuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Zahoor ul haq","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac O.","family":"Ajadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence A.","family":"Olatunji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2023.116604_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2019.108742","article-title":"Very low dose spironolactone protects experimentally-induced polycystic ovarian syndrome from insulin-resistant metabolic disturbances by suppressing elevated circulating testosterone","volume":"310","author":"Adeyanju","year":"2019","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.taap.2023.116604_bb0010","article-title":"The glucose metabolism disorder and dyslipidemia among girls with different phenotype polycystic ovary syndrome","volume":"24","author":"Akbarzadeh","year":"2019","journal-title":"J. Res. Med. Sci.: Off. J. Isfahan Univ. Med. Sci."},{"issue":"1","key":"10.1016\/j.taap.2023.116604_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2019-000352","article-title":"Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome","volume":"7","author":"Asfari","year":"2020","journal-title":"BMJ Open Gastroenterol."},{"issue":"1","key":"10.1016\/j.taap.2023.116604_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43042-019-0031-4","article-title":"Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review","volume":"20","author":"Ashraf","year":"2019","journal-title":"Egypt. J. Med. Human Genet."},{"issue":"3","key":"10.1016\/j.taap.2023.116604_bb0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2265.1993.tb01013.x","article-title":"Polycystic ovaries are a common finding in untreated female to male transsexuals","volume":"38","author":"Balen","year":"1993","journal-title":"Clin. Endocrinol."},{"issue":"7","key":"10.1016\/j.taap.2023.116604_bb0030","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jsxm.2021.05.003","article-title":"Anti-androgenic effects comparison between cyproterone acetate and spironolactone in transgender women: a randomized controlled trial","volume":"18","author":"Burinkul","year":"2021","journal-title":"J. Sex. Med."},{"key":"10.1016\/j.taap.2023.116604_bb0035","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3389\/fmolb.2022.888194","article-title":"Key genes associated with non-alcoholic fatty liver disease and polycystic ovary syndrome","volume":"9","author":"Chen","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"6","key":"10.1016\/j.taap.2023.116604_bb0040","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.fjc.0000248236.43760.86","article-title":"2006. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy","volume":"48","author":"de Resende","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.taap.2023.116604_bb0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrendo.2010.217","article-title":"Polycystic ovary syndrome: etiology, pathogenesis and diagnosis","volume":"7","author":"Goodarzi","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"2","key":"10.1016\/j.taap.2023.116604_bb0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.arcmed.2003.10.005","article-title":"Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease","volume":"35","author":"Kafali","year":"2004","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.taap.2023.116604_bb0060","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/2647865","article-title":"Cardiometabolic risk in hyperlipidemic men and women","volume":"2016","author":"Leutner","year":"2016","journal-title":"Int. J. Endocrinol."},{"key":"10.1016\/j.taap.2023.116604_bb0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00381883","article-title":"Ovarian innervation develops before initiation of folliculogenesis in the rat","volume":"270","author":"Malamed","year":"1992","journal-title":"Cell Tissue Res."},{"issue":"4","key":"10.1016\/j.taap.2023.116604_bb0070","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.3390\/ijms22041667","article-title":"Oxidative stress and low-grade inflammation in polycystic ovary syndrome: controversies and new insights","volume":"22","author":"Mancini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.taap.2023.116604_bib101","first-page":"2115","article-title":"Waist-to-height ratio (WHtR) and triglyceride to HDL-C ratio (TG\/HDL-c) as predictors of cardiometabolic risk","volume":"31","author":"Miralles","year":"2015","journal-title":"Nutrici\u00f3n hospitalaria"},{"key":"10.1016\/j.taap.2023.116604_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115381","article-title":"Low dose spironolactone-mediated androgen-adiponectin modulation alleviates endocrine-metabolic disturbances in letrozole-induced PCOS","volume":"411","author":"Olaniyi","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.taap.2023.116604_bb0080","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.det.2010.03.011","article-title":"Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss","volume":"28","author":"Rathnayake","year":"2010","journal-title":"Dermatol. Clin."},{"issue":"1","key":"10.1016\/j.taap.2023.116604_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0503-4","article-title":"PCSK9 inhibition: the way forward in the treatment of dyslipidemia","volume":"13","author":"Stoekenbroek","year":"2015","journal-title":"BMC Med."},{"issue":"3","key":"10.1016\/j.taap.2023.116604_bb0090","first-page":"299","article-title":"Fatty liver and lipotoxicity","volume":"1801","author":"Trauner","year":"2010","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Biol. Lipid."},{"key":"10.1016\/j.taap.2023.116604_bb0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.metabol.2019.02.002","article-title":"Role of PCSK9 in lipid metabolic disorders and ovarian dysfunction in polycystic ovary syndrome","volume":"94","author":"Wang","year":"2019","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.taap.2023.116604_bb0100","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1038\/s41598-021-86697-y","article-title":"Non-alcoholic fatty liver disease in polycystic ovary syndrome women","volume":"11","author":"Won","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.taap.2023.116604_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-018-0686-8","article-title":"Atherogenic index of plasma is a novel and better biomarker associated with obesity: a population-based cross-sectional study in China","volume":"17","author":"Zhu","year":"2018","journal-title":"Lipids Health Dis."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002430?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X23002430?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:01:40Z","timestamp":1758574900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X23002430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":21,"alternative-id":["S0041008X23002430"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2023.116604","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose spironolactone combats dyslipidemia and hepatic inflammation by modulating PCSK9 in rat model of polycystic ovarian syndrome","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2023.116604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116604"}}